RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

NCT04525014 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Low Enrollment

Conditions

Brain Tumor, Recurrent
Brain Tumor, Pediatric
Central Nervous System Neoplasms
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG: RRx-001
DRUG: Temozolomide
DRUG: Irinotecan

Sponsor

EpicentRx, Inc.

Collaborators

[object Object]